The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation.
The following will also be investigated:
* Survival * Remission and Relapse rate * Engraftment or graft failure * Graft versus Host Disease (GvHD)
Informed consent signed by the patient capable of giving
Patient scheduled for allogeneic transplantation within the next 3 weeks
Age ≥ 18 years
AML in first or second complete remission (CR) or complete remission with incomplete hematologic recovery (CRi/CRh) or morphologic leukemia-free state (MLFS)
Patients with acute promyelocytic leukemia with t(15;17)(q22;q12)
Patients with graft failure after previous allogeneic HCT
Patients with scheduled 2nd allogeneic HCT within 12 months after 1st allogeneic HCT
Pretreatment with either melphalan or treosulfan within the last 12 months prior to randomization
Technische Universität Dresden
Lead sponsor
medac GmbH
Collaborator